VOR
Vor Biopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$769.10M
P/E Ratio
—
EPS
$-70.50
Beta
1.92
52W High
$65.80
52W Low
$2.62
50-Day MA
$14.26
200-Day MA
$23.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Vor Biopharma Inc
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-339.05M |
| Operating Margin | 0.00% |
| Return on Equity | -125.40% |
| Return on Assets | -70.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-8.10 |
| Price-to-Book | 0.66 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.09 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $48.85M |
| Float | $34.53M |
| % Insiders | 4.80% |
| % Institutions | 62.37% |
Analyst Ratings
Consensus ($37.62 target)
1
Strong Buy7
Buy1
HoldData last updated: 4/9/2026